At the recent Heart Rhythm 2019 meeting, we spoke with Dr Douglas Packer (Cardiac Electrophysiologist, Cardiologist and Internist, Mayo Clinic Hospital, Saint Mary’s Campus, Rochester, MN, USA) about the CABANA trial and the limitations of current drug therapy for atrial fibrillation.
Filmed at Heart Rhythm 2019, San Francisco, CA, USA.
Speaker’s Disclosures: Douglas Packer has provided consulting services for Abbott, Biosense Webster Inc., Biotronik, Boston Scientific, CardioFocus, Johnson & Johnson, MediaSphere Medical, LLC, Medtronic, St Jude Medical, Siemens, SigNum Preemptive Healthcare, Inc., Spectrum Dynamics and Thermedical. He receives research funding from Abbott, Biosense Webster, Boston Scientific/EPT, CardioInsight, CardioFocus, Endosense, Hansen Medical, Medtronic, NIH, Roberston Foundation, St Jude Medical, Siemens and Thermedical. He has financial interests in mapping technology through St Jude Medical and Mayo Clinic, has equity in External Beam Ablation Medical Devices and receives royalties from Wiley & Sons, Oxford and St Jude Medical.
1. What are the limitations of current drug therapy for atrial fibrillation? (0:09)
2. What was the rationale behind the Catheter ABlation vs ANtiarrhythmic Drug Therapy in Atrial Fibrillation (CABANA) trial? (0:58)
3. What were the outcomes of the CABANA trial? (1:39)
4. What were the limitations of the study? (5:04)
5. What impact do you think the results will have on the management of atrial fibrillation? (6:01)
6. What do you have planned for the future? (7:53)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed in partnership with Arrhythmia Alliance.
Share this Video
Related Videos In Atrial Fibrillation
Michiel Rienstra and Bao-Oanh Nguyen, EHRA 2021 – Long-term Outcomes of the RACE 3 Trial
Professor Michiel Rienstra and Dr Bao-Oanh Nguyen (University Medical Center Groningen, Groningen, The Netherlands) gave us an overview of the RACE-3 study (NCT00877643) from the European Heart Rhythm Association (EHRA) Virtual Meeting 2021. Questions: What is the rationale for targeted therapy of underlying conditions in patients with persistent atrial fibrillation (AF) and mild to moderate […]
Faizel Osman, A-A Heart Rhythm Updates 2021: 2020 ESC AF Guidelines
We spoke to Professor Faizel Osman (Consultant Cardiologist and Electrophysiologist, University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK) who gave us an update about the recent new ESC Guidelines for Atrial Fibrillation and the upcoming Arrhythmia Alliance Heart Rhythm Updates 2021. Questions What are the most important new recommendations in the 2020 ESC atrial […]
Suneet Mittal, AF Symposium 2021: Atrial Fibrillation in the Post-COVID-19 Environment
We spoke to Dr Suneet Mittal (Director of Electrophysiology, The Valley Hospital, Ridgewood, NJ, USA) about the workflow innovations for atrial fibrillation ablation in the post-COVID-19 environment. Questions What have been the main challenges to atrial fibrillation (AF) ablation workflow during the COVID-19 pandemic? (0.14) What workflow innovations have been created and incorporated over the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!